NCT03918317撤回不适用
A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Rate of successful reconstructions following radiation therapy
研究概览
简要总结
This study seeks to to determine the efficacy and side effect profile following radiation therapy for participants with the AeroForm device placed. The AeroForm device is FDA approved.
详细描述
Primary objective:
To assess the proportion of successful initial phase of tissue expander/implant based breast reconstructions (no reconstruction failure or unexpected return to the operating room) following post-mastectomy radiation therapy in participants with AeroFormplaced.
Secondary objectives:
- To evaluate the rate of successful exchange of tissue expander for implant
- To evaluate the rate of reconstruction revisions
- To evaluate CTCAE acute and chronic toxicity rates, infections and cosmetic outcomes
- To evaluate dosimetry to treatment targets as well as organs at risk (heart, lungs) with AeroFormas compared to traditional reconstruction techniques.
- To evaluate time to initiation of chemotherapy and/or radiotherapy.
- To evaluate clinical outcomes-local recurrence, regional recurrence, distant metastases, survival
- To evaluate participant breast reconstruction related QOL with the AirXpander AeroFormdevice
This is a phase II trial evaluating the use of the intervention in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have histologically of invasive breast cancer.
- •Subjects must be planned for unilateral mastectomy
- •Subjects must be planned for reconstruction. Pre-pectoral or sub-pectoral reconstruction allowed. Final reconstruction must be implant
- •ECOG Performance status <2
- •Subject must have features that will necessitate post-mastectomy radiation therapy:
- •Tumors > 5 cm
- •Axillary node positive disease (pathologic confirmation)
- •Clinical features prior to neoadjuvant chemotherapy to require post-mastectomy radiation therapy
- •Recurrent disease without previous radiation
- •Clinically node negative participants with positive SLN at surgery
- •Internal mammary nodal involvement (clinical assessment)
- •Subjects must have no clinical or radiographic evidence of distant metastases (imaging not required unless indicated as part of standard of care)
- •Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving CT simulation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Subjects must have the ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Subjects with metastatic disease
- •Subjects receiving any other investigational agents.
- •Subjects treated with non-standard radiotherapy (hypofractionation, hyperfractionation, partial breast/axilla)
- •Subjects with active infection requiring IV antibiotics
- •Subject has a history or current evidence of any condition, therapy, or laboratoryabnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Subject has received prior radiation therapy to neck, breast, or chest or other area that will result in overlap.
- •Pregnant or breastfeeding women or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last day of trial treatment are excluded from this study because of the potential toxicities of radiation therapy. Additionally, because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with AirXpanders, breastfeeding women will be excluded. These potential risks may also apply to other agents used in this study.
研究组 & 干预措施
AirXpanders AeroFormtissue expander + Radiation therapy
Experimental
AirXpanders AeroFormtissue expander in participants with breast cancer undergoing post-mastectomy radiation therapy in order to define the toxicity profile and associated subsequent successful surgical reconstruction rate.
干预措施: AirXpanders AeroFormtissue expander (Device)
结局指标
主要结局
Rate of successful reconstructions following radiation therapy
时间窗: up to 6 months following permanent implant placement
次要结局
- Quality of life based on the BREAST-Q scales(up to 6 months following permanent implant placement)
- Quality of life based on the Breast satisfactions scales(up to 6 months following permanent implant placement)
- Rate of implant success at 6months following replacement.(up to 6 months following permanent implant placement)
- Time to implant exchange from Aeroform placement.(up to 6 months following permanent implant placement)
- Time to initiation of adjuvant chemotherapy following initial surgery (when applicable).(up to 6 months following permanent implant placement)
- Rate of reconstruction revisions from Aeroform placement throughout study.(up to 6 months following permanent implant placement)
- Chronic toxicity per CTCAE, Baker scoring(up to 6 months following permanent implant placement)
- Time to initiation of radiation therapy following initial surgery(up to 6 months following permanent implant placement)
- Cosmetic outcomes per the aesthetics scale(up to 6 months following permanent implant placement)
- Number of participants who experience acute toxicity per CTCAE version 4.0(up to 6 months following permanent implant placement)
研究者
相似试验
已完成
不适用
Patient Controlled Tissue Expansion for Breast ReconstructionBreast CancerNCT01425268AirXpanders, Inc.158
已完成
2 期
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)Lung CancerNCT00673738H. Lee Moffitt Cancer Center and Research Institute27
Unknown
1 期
Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in ChildrenChildhood RhabdomyosarcomaNCT03868852Xinhua Hospital, Shanghai Jiao Tong University School of Medicine48
撤回
不适用
An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"Ductal Carcinoma In SituInvasive Ductal CarcinomaNCT04349111Xoft, Inc.
招募中
不适用
Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung CancerSmall Cell Lung CarcinomaNCT06529081Copernicus Memorial Hospital165